Annual General Meeting 2017 in Karo Pharma AB (publ)

STOCKHOLM, Sweden, May 11, 2017 – At today’s Annual General Meeting in Karo Pharma the following main resolutions were passed.

The AGM voted in favour of adopting the income statements and balance sheets for the Group and the parent company. The AGM decided that funds at the disposal of the general meeting, amounting to SEK 686 855 101, including the profit for the year amounting to SEK 74 611 722, should be disposed as follows:

· A dividend per share of SEK 0,50, amounting to SEK 41 083 195,60
· To be carried forward, SEK 645 771 905,50

The AGM further discharged the Board members and the CEO from liability and resolved that the Board shall consist of five ordinary members and no deputy member. The AGM re-elected the ordinary Board members Anders Lönner, Thomas Hedner, Per-Anders Johansson and elected Marianne Hamilton and Håkan Åström as new Board members. Anders Lönner was elected Chairman of the Board..

The AGM resolved that the Board’s fees shall be SEK 450,000 for the Chairman of the Board and SEK 175,000 for each of the other members of the Board.

The accounting firm PricewaterhouseCoopers AB was re-elected as the company’s auditor until the AGM 2018.

The AGM resolved in accordance with the proposal of the nomination committee on principles for the nomination committee.

The AGM resolved in accordance with the Board’s proposal on guidelines for remuneration of executive management. The Board was authorized to, on one or several occasions prior to the next annual general, resolve on new share issues. The number of shares to be issued by virtue of the authorization shall not exceed 10 per cent of the registered share capital at the time of the share issue resolution. The new share may be made with our without deviation from the shareholders’ pre-emption right and with or without terms of issue in kind or set-off or other terms.  

For further information, please contact:  
Henrik Palm, CFO, telephone +46 70 540 40 14 or e-mail

About Karo Pharma  
Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.

The information in this report is such that Karo Pharma is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on May 11, 2017 at 8.00 p.m. CET.

This press release is also available on and 

Belonging documents

Press release (PDF)